Home
How It Works
Solutions
Resources
Events
Blog
Case Studies
For Academic Experts
Sign Up
Login

Work with thought leaders and academic experts in Pharmacology

Companies can greatly benefit from working with experts in the field of Pharmacology. These researchers possess in-depth knowledge of drug interactions, mechanisms of action, and therapeutic applications. By collaborating with them, companies can enhance their research and development efforts, gain insights into new drug targets, optimize drug formulations, and improve clinical trial design. Pharmacology experts can also provide valuable guidance in regulatory affairs, ensuring compliance with safety and efficacy standards. Additionally, their expertise can help companies identify potential drug-drug interactions and adverse effects, leading to safer and more effective medications. Overall, partnering with Pharmacology thought leaders can accelerate innovation, improve product quality, and drive business growth.

Researchers on NotedSource with backgrounds in Pharmacology include Aimee Eggler, Elvira Forte, Susan Song, MD/PhD, Regan Hamel, Dr. Everson A Nunes, Ph.D., Dushani L. Palliyaguru, Ph.D., Denver Ncube, Ph.D., Dr. David Siderovski, Ph.D., Katie Barr, Jeffrey Townsend, Lindsay Webb, PhD, and Laura Schulze.

Aimee Eggler

Villanova, Pennsylvania, United States of America
Professor of Chemistry and Biochemistry at Villanova University
Most Relevant Research Expertise
Pharmacology
Other Research Expertise (18)
Biochemistry
Physiology (medical)
Toxicology
Organic Chemistry
Clinical Biochemistry
And 13 more
About
Dr. Eggler has 20 years of experience in the field of redox biology, with a focus on the Nrf2 transcription factor, a master regulator of antioxidant, detoxification and anti-inflammatory genes. She is also an award-winning educator and the recipient of the Villanova University Junior Faculty Excellence in Teaching award. Her interests in education include innovation in teaching metabolism from a logic-based perspective.
Most Relevant Publications (1+)

25 total publications

Solving the Problem of Assessing Synergy and Antagonism for Non-Traditional Dosing Curve Compounds Using the DE/ZI Method: Application to Nrf2 Activators

Frontiers in Pharmacology / Jun 07, 2021

Repash, E. M., Pensabene, K. M., Palenchar, P. M., & Eggler, A. L. (2021). Solving the Problem of Assessing Synergy and Antagonism for Non-Traditional Dosing Curve Compounds Using the DE/ZI Method: Application to Nrf2 Activators. Frontiers in Pharmacology, 12. https://doi.org/10.3389/fphar.2021.686201

See Full Profile

Elvira Forte

New York, New York, United States of America
Scientific strategist • Senior Scientist • Senior Scientific Editor
Most Relevant Research Expertise
Pharmacology
Other Research Expertise (26)
fibrosis
inflammation
cardiomyopathies
Physiology
Cardiology and Cardiovascular Medicine
And 21 more
About
Motivated and growth-driven biomedical scientist with over 15 years of experience in the cardiovascular field. Strong background in cell and molecular biology, data analysis, and interpretation. Seeking #newopportunities to deliver value as a Senior Scientist, Associate Principal Scientist, Scientific Liaison, or Scientific Consultant within a company that combines new technologies such as single-cell omics and AI for drug discovery and personalized medicine. <br> Throughout my career, I've used various in vivo and in vitro models to investigate the molecular and cellular mechanisms of fibrosis and inflammation in the heart, and how these mechanisms are affected in mice with different genetic backgrounds. My experience includes project management and mentoring. I completed three projects involving international collaborations, supervised two junior researchers, and taught cellular and molecular techniques to at least six professionals. As one of the launching editors and senior editor at Nature Cardiovascular Research, I oversaw the quality of the content published in the journal and the editorial process. I collaborated with authors, reviewers, and editors to ensure the highest standards of scientific rigor, relevance, and innovation. I also contributed to the journal's vision, strategy, and outreach, promoting the latest advances and discoveries in the cardiovascular and hematology fields. This experience has sharpened my analytical and communication skills and broadened my understanding of the field, covering a wide range of studies, from basic research to clinical, epidemiological, and public health research. My mission is to advance the knowledge and practice of cardiovascular medicine and to bridge the gap between research and clinical applications. Keywords: cardiovascular, #fibrosis, inflammation, cardioimmunology, RNA, single-cell biology, #transcriptomics, imaging, animal models, small animal surgery, and scientific writing.
Most Relevant Publications (1+)

63 total publications

New Perspectives to Repair a Broken Heart

Cardiovascular &amp; Hematological Agents in Medicinal Chemistry / Apr 01, 2009

Gaetani, R., Barile, L., Forte, E., Chimenti, I., Ionta, V., Di Consiglio, A., Miraldi, F., Frati, G., Messina, E., & Giacomello, A. (2009). New Perspectives to Repair a Broken Heart. Cardiovascular &amp; Hematological Agents in Medicinal Chemistry, 7(2), 91–107. https://doi.org/10.2174/187152509787847128

See Full Profile

Susan Song, MD/PhD

Pittsburgh, Pennsylvania, United States of America
Research Assistant Professor in Neuroscience at University of Pittsburgh
Most Relevant Research Expertise
Pharmacology
Other Research Expertise (15)
microglia
white matter
neurodegenerative disease
Cellular and Molecular Neuroscience
Neurology
And 10 more
About
Susan Song, MD/PhD, is a highly accomplished neuroscientist, with extensive education and experience in the field. She received her MD/PhD in Neurology and Neuroscience from Southern Medical University in 2015, where she conducted groundbreaking research on the molecular mechanisms of neurodegenerative diseases. Following this, she completed a post-doctoral fellowship in Neuroscience at the University of Pittsburgh, where she continued to excel in her research and received numerous awards and grants for her work. Dr. Song's expertise lies in studying the underlying causes and potential treatments for various neurological diseases, such as ischemic stroke, traumatic brain injury, glioblastoma, Alzheimer's disease, and multiple sclerosis. She has a deep understanding of the brain and nervous system, and is constantly seeking new ways to unravel the complexities of these diseases. Dr. Song has held several prestigious positions throughout her career, including her current position as Research Assistant Professor at the University of Pittsburgh. She has published numerous articles in top scientific journals and presented her research at international conferences. Her findings have contributed greatly to the field of neurology and have the potential to improve the lives of millions of people suffering from neurological disorders. Overall, Dr. Song is a highly respected and accomplished physician-scientist who is making significant contributions to the field of neurology. With her extensive education, diverse experience, and unwavering dedication to her patients, she is a true leader in the field and a valuable asset to the medical community.

See Full Profile

Regan Hamel

Cambridge
Senior bioinformatics scientist, specializing in single cell omics in the context of cellular reprogramming and neuroinflammation
Most Relevant Research Expertise
Pharmacology
Other Research Expertise (12)
single cell biology
transcriptomics
Cellular and Molecular Neuroscience
Cell Biology
Developmental Biology
And 7 more
About
Regan Hamel has an MPhil and PhD in Clinical Neurosciences from University of Cambridge. She also has a Bachelor of Science in Neurosciences from McGill University. Her PhD with Stefano Pluchino and John Marioni focused on single cell transcriptomics in the context of neuroinflammation. Since 2021 she has worked as a Bioinformatics scientist at Mogrify Ltd, applying a multitude of computational biology techniques (including single cell omics, bulk RNAseq, and predictive modelling) in the context of cell reprogramming
Most Relevant Publications (1+)

12 total publications

Combination of In Situ Lcn2 pRNA-RNAi Nanotherapeutics and iNSC Transplantation Ameliorates Experimental SCI in Mice

Molecular Therapy / Dec 01, 2020

Braga, A., Bandiera, S., Verheyen, J., Hamel, R., Rutigliani, C., Edenhofer, F., Smith, J. A., & Pluchino, S. (2020). Combination of In Situ Lcn2 pRNA-RNAi Nanotherapeutics and iNSC Transplantation Ameliorates Experimental SCI in Mice. Molecular Therapy, 28(12), 2677–2690. https://doi.org/10.1016/j.ymthe.2020.08.001

See Full Profile

Dr. Everson A Nunes, Ph.D.

Hamilton, Ontario, Canada
Post-Doctoral Fellow at McMaster University | former Associate Professor - Physiological Sciences
Most Relevant Research Expertise
Pharmacology
Other Research Expertise (39)
skeletal muscle
nutrition
physical activity
obesity
cancer
And 34 more
About
Dr. Everson A Nunes is a highly accomplished researcher and educator in the field of physiological sciences. He received his Ph.D. in Cellular and Molecular Biology with a focus on Physiological Sciences from Universidade Federal do Paraná in 2009, after completing a BSc in Human Nutrition and an MSc in Physiological Sciences. He also holds a specialization in Exercise Physiology and a BSc in Biological Sciences from Universidade Federal do Paraná. Dr. Nunes has a strong background in research, having completed two post-doctoral fellowships at McMaster University and Universidade Federal do Paraná. He has also held positions as an associate professor and assistant professor at Universidade Federal de Santa Catarina. He has published numerous articles in peer-reviewed journals, and his research focuses on the effects of exercise and nutrition on physiological processes in the human body. In addition to his research, Dr. Nunes is also a dedicated educator. He has taught at various universities in Brazil, including Universidade Federal de Santa Catarina, Universidade Gama Filho, Faculdades Integradas Espírita, Pontificia Universidade Católica do Paraná, and Faculdade do Litoral Sul. He is known for his dynamic teaching style and his ability to engage students in complex physiological concepts. Dr. Nunes is a member of several professional organizations, including the American Society for Nutrition, the Canadian Society of Exercise Physiology, the Canadian Nutrition Society and the Brazilian Society of Physiology. He is also a regular speaker at national and international conferences, sharing his expertise and research findings with colleagues and students. Overall, Dr. Nunes is a highly qualified and experienced professional in physiological sciences, metabolism, cancer and nutrition. His dedication to research and education makes him a valuable asset to any institution.
Most Relevant Publications (2+)

97 total publications

Age- and gender-related changes in glucose homeostasis in glucocorticoid-treated rats

Canadian Journal of Physiology and Pharmacology / Oct 01, 2014

dos Santos, C., Ferreira, F. B. D., Gonçalves-Neto, L. M., Taboga, S. R., Boschero, A. C., & Rafacho, A. (2014). Age- and gender-related changes in glucose homeostasis in glucocorticoid-treated rats. Canadian Journal of Physiology and Pharmacology, 92(10), 867–878. https://doi.org/10.1139/cjpp-2014-0259

Implications of Palmitoleic Acid (Palmitoleate) On Glucose Homeostasis, Insulin Resistance and Diabetes

Current Drug Targets / Mar 30, 2017

Nunes, E., & Rafacho, A. (2017). Implications of Palmitoleic Acid (Palmitoleate) On Glucose Homeostasis, Insulin Resistance and Diabetes. Current Drug Targets, 18(6), 619–628. https://doi.org/10.2174/1389450117666151209120345

See Full Profile

Dushani L. Palliyaguru, Ph.D.

Baltimore, MD, Maryland, United States of America
Toxicologist | Aging, Nutrition and Metabolism Research Scientist | Systems Biologist
Research Expertise (17)
Nutrition
aging
Oncology
Hematology
Molecular Biology
And 12 more
About
·   Highly productive scientist with 13 years of multidisciplinary experience in toxicology, molecular nutrition, and aging/ disease biomarkers ·   Excellent communicator with proven record of advanced writing and presentation skills - manuscripts, conference presentations, and grants ·   Extensive experience in large study design, supervision and coordination, big data analysis, and management of junior scientists

See Full Profile

Denver Ncube, Ph.D.

Morrisville, North Carolina, United States of America
Computational biologist/bioinformatician with a passion for extracting meaningful insight from complex biological data.
Most Relevant Research Expertise
Pharmacology
Other Research Expertise (4)
Neuroscience
Cell Biology
Anatomy
Toxicology
About
With over 8 years of experience in neuroscience and bioinformatics, I am a computational biologist who is passionate about applying data science and machine learning to unravel the molecular and cellular mechanisms of complex diseases, such as cancer and neurodegenerative disorders.
Most Relevant Publications (1+)

6 total publications

Comparative Hepatotoxicity of Fluconazole, Ketoconazole, Itraconazole, Terbinafine, and Griseofulvin in Rats

Journal of Toxicology / Jan 01, 2017

Khoza, S., Moyo, I., & Ncube, D. (2017). Comparative Hepatotoxicity of Fluconazole, Ketoconazole, Itraconazole, Terbinafine, and Griseofulvin in Rats. Journal of Toxicology, 2017, 1–9. https://doi.org/10.1155/2017/6746989

See Full Profile

Dr. David Siderovski, Ph.D.

Fort Worth
Professor of Computational Pharmacology; Chair of HSC SBS Dept. of Pharmacology & Neuroscience
Most Relevant Research Expertise
Pharmacology
Other Research Expertise (25)
Regulator of G protein Signaling (RGS) proteins
Molecular Biology
Cellular and Molecular Neuroscience
Molecular Medicine
Cell Biology
And 20 more
About
Dr. David Siderovski is a renowned scientist and academic, with a career spanning over two decades. He received his Ph.D. in Medical Biophysics from the University of Toronto in 1997, where he specialized in signal transduction and cellular signaling pathways. After completing his doctorate, Dr. Siderovski held various faculty positions at prestigious universities, including the University of North Carolina at Chapel Hill, West Virginia University School of Medicine, and the University of North Texas Health Science Center. At these institutions, Dr. Siderovski has made significant contributions to the field of pharmacology through his research on G protein-coupled receptors (GPCRs) and RGS proteins, which are key regulators of GPCR cellular signaling. His work has helped to advance the understanding of RGS proteins and their roles in various diseases, including cancer, cardiovascular disorders, and neurological disorders. In addition to his research, Dr. Siderovski is also a dedicated educator and mentor. He has taught and mentored numerous undergraduate, graduate, and medical students, and has served as a mentor for postdoctoral fellows and junior faculty members. He is known for his passion and enthusiasm for science and his ability to inspire and guide the next generation of scientists. Dr. Siderovski has received numerous awards and honors for his contributions to the scientific community. He was the recipient of the Abel Award in 2004 from the American Society of Pharmacology & Experimental Therapeutics for his pioneering discoveries of the RGS proteins and the GoLoco motif. He has also served on editorial boards of several scientific journals (including a decade at *J.Biol.Chem.*) and has been a member of various scientific committees, NIH study section panels, and pharma/biotech advisory boards, including for Inspire, Wyeth, and BellBrook Labs. Overall, Dr. David Siderovski is a highly accomplished and respected scientist and educator, whose research has had a significant impact on the field of pharmacology. His dedication and passion for science continue to inspire and influence the next generation of researchers in this field.
Most Relevant Publications (7+)

94 total publications

G-protein signaling: back to the future

Cellular and Molecular Life Sciences / Mar 01, 2005

McCudden, C. R., Hains, M. D., Kimple, R. J., Siderovski, D. P., & Willard, F. S. (2005). G-protein signaling: back to the future. Cellular and Molecular Life Sciences, 62(5), 551–577. https://doi.org/10.1007/s00018-004-4462-3

Regulators of G-Protein signalling as new central nervous system drug targets

Nature Reviews Drug Discovery / Mar 01, 2002

Neubig, R. R., & Siderovski, D. P. (2002). Regulators of G-Protein signalling as new central nervous system drug targets. Nature Reviews Drug Discovery, 1(3), 187–197. https://doi.org/10.1038/nrd747

Regulators of G-Protein Signaling and Their Gα Substrates: Promises and Challenges in Their Use as Drug Discovery Targets

Pharmacological Reviews / Jul 07, 2011

Kimple, A. J., Bosch, D. E., Giguère, P. M., & Siderovski, D. P. (2011). Regulators of G-Protein Signaling and Their Gα Substrates: Promises and Challenges in Their Use as Drug Discovery Targets. Pharmacological Reviews, 63(3), 728–749. https://doi.org/10.1124/pr.110.003038

Receptor-Mediated Activation of Heterotrimeric G-Proteins: Current Structural Insights

Molecular Pharmacology / Apr 12, 2007

Johnston, C. A., & Siderovski, D. P. (2007). Receptor-Mediated Activation of Heterotrimeric G-Proteins: Current Structural Insights. Molecular Pharmacology, 72(2), 219–230. https://doi.org/10.1124/mol.107.034348

Chronic Olanzapine Treatment Causes Differential Expression of Genes in Frontal Cortex of Rats as Revealed by DNA Microarray Technique

Neuropsychopharmacology / Jan 11, 2006

Fatemi, S. H., Reutiman, T. J., Folsom, T. D., Bell, C., Nos, L., Fried, P., Pearce, D. A., Singh, S., Siderovski, D. P., Willard, F. S., & Fukuda, M. (2006). Chronic Olanzapine Treatment Causes Differential Expression of Genes in Frontal Cortex of Rats as Revealed by DNA Microarray Technique. Neuropsychopharmacology, 31(9), 1888–1899. https://doi.org/10.1038/sj.npp.1301002

Gα12/13- and Rho-Dependent Activation of Phospholipase C-ϵ by Lysophosphatidic Acid and Thrombin Receptors

Molecular Pharmacology / Mar 22, 2006

Hains, M. D., Wing, M. R., Maddileti, S., Siderovski, D. P., & Harden, T. K. (2006). Gα12/13- and Rho-Dependent Activation of Phospholipase C-ϵ by Lysophosphatidic Acid and Thrombin Receptors. Molecular Pharmacology, 69(6), 2068–2075. https://doi.org/10.1124/mol.105.017921

Induction of Regulator of G-Protein Signaling 2 Expression by Long-Acting β2-Adrenoceptor Agonists and Glucocorticoids in Human Airway Epithelial Cells

Journal of Pharmacology and Experimental Therapeutics / Oct 25, 2013

Holden, N. S., George, T., Rider, C. F., Chandrasekhar, A., Shah, S., Kaur, M., Johnson, M., Siderovski, D. P., Leigh, R., Giembycz, M. A., & Newton, R. (2013). Induction of Regulator of G-Protein Signaling 2 Expression by Long-Acting β2-Adrenoceptor Agonists and Glucocorticoids in Human Airway Epithelial Cells. Journal of Pharmacology and Experimental Therapeutics, 348(1), 12–24. https://doi.org/10.1124/jpet.113.204586

See Full Profile

Katie Barr

Warrington
Bioinformatician and developer with strong academic and commercial experience
Most Relevant Research Expertise
Pharmacology
Other Research Expertise (11)
Computer Science Applications
Atomic and Molecular Physics, and Optics
Bioengineering
Pharmacology (medical)
Biochemistry (medical)
And 6 more
About
Katie Barr is a bioinformatician with a strong background in computer science. She received her Ph.D in Quantum Information from the University of Leeds in 2013. She also holds an MSc in Mathematical logic and the theory of computation from the University of Manchester, and a BSc in Physics and Philosophy with study in Continental Europe from the University of Bristol. Katie has extensive experience working in the fields of bioinformatics and software development. She has worked as a scientific programmer at the Earlham Institute, a postdoctoral bioinformatician in the Nanomedicine group at the University of Manchester, and is now an Associate Principal Scientist in Bioinformatics at Kromek. Katie is passionate about using her knowledge and skills to improve the lives of others and she is dedicated to the advancement of science and technology. She believes in the power of collaboration and works to create meaningful partnerships between industry and academia.
Most Relevant Publications (1+)

9 total publications

Deep Tissue Translocation of Graphene Oxide Sheets in Human Glioblastoma 3D Spheroids and an Orthotopic Xenograft Model

Advanced Therapeutics / Oct 09, 2020

de Lázaro, I., Sharp, P., Gurcan, C., Ceylan, A., Stylianou, M., Kisby, T., Chen, Y., Vranic, S., Barr, K., Taheri, H., Ozen, A., Bussy, C., Yilmazer, A., & Kostarelos, K. (2020). Deep Tissue Translocation of Graphene Oxide Sheets in Human Glioblastoma 3D Spheroids and an Orthotopic Xenograft Model. Advanced Therapeutics, 4(1). Portico. https://doi.org/10.1002/adtp.202000109

See Full Profile

Jeffrey Townsend

New Haven, CT
Professor of Biostatistics and Ecology & Evolutionary Biology
Most Relevant Research Expertise
Pharmacology
Other Research Expertise (52)
Evolutionary Genomics
Microbiology
Infectious Diseases
Genetics
Cell Biology
And 47 more
About
Jeffrey Townsend is a Professor of Organismic and Evolutionary Biology at Yale University. He received his Ph.D. from Harvard University in 2002 and his Sc.B. from Brown University in 1994. He has been a teacher at St. Ann's School and an Assistant Professor at the University of Connecticut. He is currently the Elihu Professor of Biostatistics at Yale University.
Most Relevant Publications (1+)

207 total publications

Retrospective evidence for a biological cost of vancomycin resistance determinants in the absence of glycopeptide selective pressures

Journal of Antimicrobial Chemotherapy / Jan 07, 2011

Johnsen, P. J., Townsend, J. P., Bohn, T., Simonsen, G. S., Sundsfjord, A., & Nielsen, K. M. (2011). Retrospective evidence for a biological cost of vancomycin resistance determinants in the absence of glycopeptide selective pressures. Journal of Antimicrobial Chemotherapy, 66(3), 608–610. https://doi.org/10.1093/jac/dkq512

See Full Profile

Lindsay Webb, PhD

Immunologist and cancer biologist passionate about driving innovative research to improve patient health
Most Relevant Research Expertise
Pharmacology
Other Research Expertise (6)
Cancer Research
Immunology and Allergy
Molecular Medicine
Oncology
Immunology
And 1 more
About
Immunologist with expertise in T cell biology and molecular mechanisms of inflammation and anti-tumor immunity. Expert in drug development of biologics and cell therapies from early discovery to IND-enabling studies for oncology and autoimmune indications.
Most Relevant Publications (3+)

11 total publications

203 A membrane-tethered IL-15/IL-15 receptor fusion protein enhances the persistence and efficacy of CD70-targeted TRuC-T cells

Journal for ImmunoTherapy of Cancer / Nov 01, 2021

Ding, J., Webb, L., Patterson, T., Fleury, M., Zieba, A., Horton, H., Hofmeister, R., Gutierrez, D., & Tighe, R. (2021). 203 A membrane-tethered IL-15/IL-15 receptor fusion protein enhances the persistence and efficacy of CD70-targeted TRuC-T cells. Journal for ImmunoTherapy of Cancer, 9(Suppl 2), A214–A214. https://doi.org/10.1136/jitc-2021-sitc2021.203

173 Expression of a membrane-tethered IL-15/IL-15 receptor fusion protein enhances the persistence of MSLN-targeted TRuC-T cells

Journal for ImmunoTherapy of Cancer / Nov 01, 2021

Fleury, M., McCarthy, D., Horton, H., Anderson, C., Watt, A., Zieba, A., Webb, L., Ding, J., Tighe, R., Hofmeister, R., & Gutierrez, D. (2021). 173 Expression of a membrane-tethered IL-15/IL-15 receptor fusion protein enhances the persistence of MSLN-targeted TRuC-T cells. Journal for ImmunoTherapy of Cancer, 9(Suppl 2), A185–A185. https://doi.org/10.1136/jitc-2021-sitc2021.173

757 M9657, a novel tumor-targeted conditional anti-CD137 agonist displays MSLN-dependent anti-tumor immunity

Journal for ImmunoTherapy of Cancer / Nov 01, 2021

Xu, C., Rabinovich, B., Deshpande, A., Zhou, X., Pipp, F. C., Schweickhardt, R., Webb, L., Yalavarthi, S., Bourin, C., Ghatak, P., Safi, B., Wollerton, F., Brewis, N., Munoz-Olaya, J., Belousova, N., Alimzhanov, M., Hubensack, M., Halle, J.-P., Blaukat, A., & Moisan, J. (2021). 757 M9657, a novel tumor-targeted conditional anti-CD137 agonist displays MSLN-dependent anti-tumor immunity. Journal for ImmunoTherapy of Cancer, 9(Suppl 2), A792–A792. https://doi.org/10.1136/jitc-2021-sitc2021.757

See Full Profile

Laura Schulze

TORONTO, Ontario, Canada
Passionate mental health researcher with a PhD in Neuroscience, dedicated to fostering innovation and empathy in accessible and holistic mental health care.
Most Relevant Research Expertise
Pharmacology
Other Research Expertise (2)
Psychiatry and Mental health
Biological Psychiatry
About
Hi! My name is Laura, and I am a mental health researcher and neuroscientist from Toronto. I have a diverse background in clinical research, industry/startup involvement, and advisory roles. My passion lies in exploring the potential of neurotech and utilizing data-driven insights to understand and support mental well-being. I also deeply value the role of community and collective well-being in fostering positive mental health outcomes.
Most Relevant Publications (4+)

8 total publications

Effect of antipsychotic pharmacotherapy on clinical outcomes of intermittent theta-burst stimulation for refractory depression

Journal of Psychopharmacology / Nov 11, 2016

Schulze, L., Remington, G., Giacobbe, P., Kennedy, S. H., Blumberger, D. M., Daskalakis, Z. J., & Downar, J. (2016). Effect of antipsychotic pharmacotherapy on clinical outcomes of intermittent theta-burst stimulation for refractory depression. Journal of Psychopharmacology, 31(3), 312–319. https://doi.org/10.1177/0269881116675516

Cognitive safety of dorsomedial prefrontal repetitive transcranial magnetic stimulation in major depression

European Neuropsychopharmacology / Jul 01, 2016

Schulze, L., Wheeler, S., McAndrews, M. P., Solomon, C. J. E., Giacobbe, P., & Downar, J. (2016). Cognitive safety of dorsomedial prefrontal repetitive transcranial magnetic stimulation in major depression. European Neuropsychopharmacology, 26(7), 1213–1226. https://doi.org/10.1016/j.euroneuro.2016.04.004

Antipsychotic response in first-episode schizophrenia: efficacy of high doses and switching

European Neuropsychopharmacology / Sep 01, 2013

Agid, O., Schulze, L., Arenovich, T., Sajeev, G., McDonald, K., Foussias, G., Fervaha, G., & Remington, G. (2013). Antipsychotic response in first-episode schizophrenia: efficacy of high doses and switching. European Neuropsychopharmacology, 23(9), 1017–1022. https://doi.org/10.1016/j.euroneuro.2013.04.010

Clinical, behavioral, and neural measures of reward processing correlate with escitalopram response in depression: a Canadian Biomarker Integration Network in Depression (CAN-BIND-1) Report

Neuropsychopharmacology / Apr 29, 2020

Dunlop, K., Rizvi, S. J., Kennedy, S. H., Hassel, S., Strother, S. C., Harris, J. K., Zamyadi, M., Arnott, S. R., Davis, A. D., Mansouri, F., Schulze, L., Ceniti, A. K., Lam, R. W., Milev, R., Rotzinger, S., Foster, J. A., Frey, B. N., Parikh, S. V., Soares, C. N., … Downar, J. (2020). Clinical, behavioral, and neural measures of reward processing correlate with escitalopram response in depression: a Canadian Biomarker Integration Network in Depression (CAN-BIND-1) Report. Neuropsychopharmacology, 45(8), 1390–1397. https://doi.org/10.1038/s41386-020-0688-x

See Full Profile

Example Pharmacology projects

How can companies collaborate more effectively with researchers, experts, and thought leaders to make progress on Pharmacology?

Optimizing Drug Formulations

A pharmaceutical company can collaborate with a Pharmacology expert to optimize the formulation of a drug, ensuring its stability, bioavailability, and therapeutic efficacy. The researcher can provide insights into the physicochemical properties of the drug, recommend suitable excipients, and suggest formulation strategies to enhance drug delivery and absorption.

Identifying New Drug Targets

By partnering with a Pharmacology researcher, a biotechnology company can identify novel drug targets for various diseases. The expert can analyze disease mechanisms, molecular pathways, and receptor interactions to identify potential therapeutic targets. This collaboration can lead to the development of innovative drugs with improved efficacy and specificity.

Improving Clinical Trial Design

A contract research organization (CRO) can collaborate with a Pharmacology expert to improve the design of clinical trials. The researcher can provide insights into appropriate dosing regimens, patient selection criteria, and outcome measures. This collaboration can enhance the efficiency and reliability of clinical trials, leading to faster drug approvals and reduced development costs.

Assessing Drug Safety and Efficacy

A pharmaceutical company can work with a Pharmacology expert to assess the safety and efficacy of their drugs. The researcher can conduct preclinical studies, evaluate drug-drug interactions, and assess potential adverse effects. This collaboration can help identify and mitigate safety risks, ensuring the development of safe and effective medications.

Navigating Regulatory Affairs

Companies can collaborate with Pharmacology experts to navigate the complex landscape of regulatory affairs. These researchers can provide guidance on regulatory requirements, assist in preparing documentation for regulatory submissions, and ensure compliance with safety and efficacy standards. This collaboration can streamline the regulatory process and expedite the approval of new drugs.